Satellos Bioscience Inc. (MSCLF)
OTC PINK OTC PINK Primary Summary
Satellos Bioscience DMD Drug Shows Early Promise in 6-Month Study Update
Satellos Bioscience NASDAQ: MSLE said interim six-month data from its ongoing TRAILHEAD study showed encouraging safety and efficacy signals for SAT-3247, its investigational therapy for Duchenne muscular dystrophy, in a small cohort of adult participants.
Satellos Bioscience: Promising Novel Treatment For Duchenne Muscular Dystrophy
Toronto-based Satellos Bioscience is a clinical-stage small molecule development company focused on restoring natural muscle repair and regeneration for degenerative muscle diseases. Its lead drug candidate SAT-3247 is an oral pill, which aims to regenerate muscle function rather than merely delay its loss. Satellos has the potential to produce substantial rewards if SAT-3247 can demonstrate sufficient muscle regeneration in DMD patients in a safe and tolerable manner.
Satellos Bioscience Inc. (MSCLF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Satellos Bioscience Inc. ever had a stock split?
Satellos Bioscience Inc. Profile
| Biotechnology Industry | Healthcare Sector | Francis Gleeson CEO | OTC PINK Exchange | 80401L308 CUSIP |
| CA Country | 14 Employees | - Last Dividend | 18 Aug 2021 Last Split | - IPO Date |
Overview
Satellos Bioscience Inc. is a pioneering biotechnology firm committed to the development of regenerative therapeutics aimed at addressing the challenges of degenerative muscle diseases. With its foundation built in 2018, the company has established its headquarters in Toronto, Canada, marking a significant presence in the field of biotechnology. By focusing on breakthrough research and development, Satellos Bioscience Inc. is dedicated to discovering and developing small molecule drugs, particularly for the treatment of Duchenne muscular dystrophy, a genetic disorder characterized by progressive muscle degeneration and weakness. The innovative approach and scientific rigor of the company underscore its potential to make significant contributions to medical science, especially in regenerative medicine.
Products and Services
- Lead Program for Duchenne Treatment:
- MyoReGenX Automated Microscopy System:
The centerpiece of Satellos Bioscience Inc.'s research is its lead program aimed at the development of a groundbreaking small molecule drug for the treatment of Duchenne muscular dystrophy. This program exemplifies the company's commitment to addressing one of the most devastating muscle degenerative diseases, offering hope through potential therapeutic solutions that could radically improve the quality of life for those affected.
Another significant innovation by Satellos Bioscience Inc. is the MyoReGenX, an advanced automated microscopy system designed to emulate the muscle stem cell environment outside the human body (ex-vivo). This tool represents a leap forward in muscle biology research, offering researchers the ability to study muscle stem cell behaviors in a controlled environment, thus accelerating the discovery and development of new therapeutics for muscle regeneration.
